39 clinical trials matched your search for Lung Cancer. You can click one of the clinical trials below for more information, or click the Search Again button to enter different search text.

Search Again
Condition Study Title Investigator
Lung Cancer Study of Therapies in Participants with Resectable (removable) and Untreated Non-Small Cell Lung Cancer (NSCLC) Catherine Shu, MD
Lung Cancer Testing Whether the Use of Brain Scans Alone vs. Brain Scans Plus Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer Simon Cheng, MD, PhD
Lung Cancer Study of Combining Osimertinib with and without Ramucirumab in Non-Small Cell Lung Cancer (NSCLC) Catherine Shu, MD
Lung Cancer Tomivosertib With Anti-PD-(L)1 in Subjects With Non-Small Cell Lung Cancer (NSCLC) Brian Henick, MD
Lung Cancer Study of Osimertinib (TAGRISSOTM) in Non-Small Cell Lung Cancer (NeoADAURA) Patients Catherine Shu, MD
Lung Cancer Study of Atezolizumab and Tiragolumab Alone or in Combination with Chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC) Catherine Shu, MD
Lung Cancer Study in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) whose Disease has Gotten Worse After Osermitinib Treatment Catherine Shu, MD
Lung Cancer Study of Pembrolizumab Alone or in Combination with Chemotherapy in Older Patients with Non-Small Cell Lung Cancer Catherine Shu, MD
Lung Cancer Liver-Directed Radiotherapy Along with Chemotherapy for Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) and Liver Metastases Brian Henick, MD
Lung Cancer Study of Berzosertib Compared to Chemotherapy for Patients with Non-Small Cell Lung Cancer Benjamin Herzberg, MD
Lung Cancer ApricityCare: Smartphone App Study for Patients with Non-Small Cell Lung Cancer (NSCLC) Brian Henick, MD
Lung Cancer Study of Savolitinib in Combination with Osimertinib vs. Chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC) Catherine Shu, MD
Lung Cancer Study of Patritumab Deruxtecan in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer (NSCLC) Catherine Shu, MD
Cancer Study of IDE196 in Patients with Solid Tumors Shaheer Khan, DO
Cancer Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs) Brian Henick, MD
Cancer TCR-engineered T Cells in Solid Tumors (ACTengine) Ran Reshef, MD
Cancer Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Catherine Shu, MD
Cancer Study of IMC-F106C Alone and in Combination With Checkpoint Inhibitors in Participants with Advanced Cancers Benjamin Izar, MD
Cancer A Study of BMS-986340 Alone and in Combination With Nivolumab in Participants With Advanced Solid Tumors Shaheer Khan, DO
Cancer Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Brian Henick, MD
Autoimmune Disorders Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Brian Henick, MD
Cancer Study of Investigational Drug (RP-6306) in Patients with Advanced Cancer Ryan Moy, MD
Cancer Study of BAY 1895344 in Combination with Chemotherapy for Patients with Advanced Cancer Mark Stein, MD
Cancer Study of RP-3500 in Combination with PARP Inhibitor for Patients with Advanced Cancer Benjamin Herzberg, MD
Cancer Study of IDE397 in Patients with Advanced Solid Tumors Benjamin Herzberg, MD
Cancer Study of CS5001 in Patients with Advanced Solid Tumors Shaheer Khan, DO
Cancer Study of BT7480 in Patients with Advanced Cancer Mark Stein, MD
Cancer Study of ASP3082 in Patients with Advanced Cancer with a KRAS G12D Mutation Benjamin Herzberg, MD
Cancer Study of STK-012 Alone or in Combination with Pembrolizumab (KEYTRUDA) in Patients with Advanced Solid Tumors Benjamin Izar, MD
Cancer Study of 68Ga-FAP-2286 and 177Lu-FAP-2286 in Patients with Advanced Cancer Ryan Moy, MD
Cancer Study of E-602 Alone or in Combination with Libtayo (Cemiplimab) in Patients with Advanced Cancer Brian Henick, MD
Cancer Study of BLU-222 Alone or in Combination with Other Cancer Therapy for Patients with Advanced Cancer Brian Henick, MD
Cancer Study of LNS8801 Alone or in Combination with Pembrolizumab in Patients with Advanced Cancer Brian Henick, MD
Cancer Study of RMC-6291 in Patients with Advanced Solid Tumors Benjamin Herzberg, MD
Cancer Study of Gavo-Cel Alone or in Combination with Nivolumab or Ipilimumab in Patients with Advanced Cancer Ran Reshef, MD
Cancer Study of ASKG915 in Patients with Advanced Solid Tumors Mark Stein, MD
Cancer Study of XL092 Alone or in Combination with Anticancer Therapy in Patients with Unresectable orMetastatic Solid Tumors Karie D. Runcie, MD
Cancer Study of MRT-2359 in Patients with Solid Tumors Benjamin Herzberg, MD
Cancer Study of RMC-6236 in Patients with Solid Tumors with a KRAS Mutation Benjamin Herzberg, MD
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE